Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner
新聞摘要
以下為來源提供的節錄，完整報道請查看原文。
Top university research, cross-border data exchanges and access to mainland China’s large market have attracted Japanese firm Rohto Pharmaceutical to conduct clinical trials in Hong Kong, making it the first company from the country to partner with the city’s government under a flagship investment initiative.